Alicia M Hinze1, Cheng T Lin2, Amira F Hussien2, Jamie Perin3, Aida Venado4, Jeffrey A Golden4, Francesco Boin5, Robert H Brown2,6,7,8, Robert A Wise7,8, Fredrick M Wigley9. 1. Department of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA. 2. Department of Radiology, Johns Hopkins University, Baltimore, MD, USA. 3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Medicine, Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, USA. 5. Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, USA. 6. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA. 7. Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8. Department of Medicine, Division of Pulmonary, MD, USA. 9. Department of Medicine, Division of Clinical and Molecular Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Abstract
OBJECTIVE: To investigate the natural history of fibrotic lung disease in recipients of a single lung transplant for scleroderma-associated interstitial lung disease (ILD). METHODS: Global ILD (including ground glass, nodular opacities and fibrosis) was categorized into severity quintiles on first and last post-transplant CT scans, and percent fibrosis by manual contouring was also determined, in nine single lung transplant recipients. Quantitative mean lung densities and volumes for the native and allograft lungs were also acquired. RESULTS: In the native lung, global ILD severity quintile worsened in two cases and percent fibrosis worsened in four cases (range 5-28%). In the lung allograft, one case each developed mild, moderate and severe ILD; of these, new fibrotic ILD (involving <10% of lung) occurred in two cases and acute cellular rejection occurred in one. The average change in native lung density over time was +2.2 Hounsfield Units per year and lung volume +1.4 ml per year, whereas the allograft lung density changed by -5.5 Hounsfield Units per year and total volume +27 ml per year (P = 0.011 and P = 0.039 for native vs allograft density and volume comparisons, respectively). CONCLUSIONS: While the course of ILD in the native and transplanted lungs varied in this series, these cases illustrate that disease progression is common in the native lung, suggesting that either the immune process continues to target autoantigens or ongoing fibrotic pathways are active in the native lung. Mild lung disease may occur in the allograft after several years due to either allograft rejection or recurrent mild ILD.
OBJECTIVE: To investigate the natural history of fibrotic lung disease in recipients of a single lung transplant for scleroderma-associated interstitial lung disease (ILD). METHODS: Global ILD (including ground glass, nodular opacities and fibrosis) was categorized into severity quintiles on first and last post-transplant CT scans, and percent fibrosis by manual contouring was also determined, in nine single lung transplant recipients. Quantitative mean lung densities and volumes for the native and allograft lungs were also acquired. RESULTS: In the native lung, global ILD severity quintile worsened in two cases and percent fibrosis worsened in four cases (range 5-28%). In the lung allograft, one case each developed mild, moderate and severe ILD; of these, new fibrotic ILD (involving <10% of lung) occurred in two cases and acute cellular rejection occurred in one. The average change in native lung density over time was +2.2 Hounsfield Units per year and lung volume +1.4 ml per year, whereas the allograft lung density changed by -5.5 Hounsfield Units per year and total volume +27 ml per year (P = 0.011 and P = 0.039 for native vs allograft density and volume comparisons, respectively). CONCLUSIONS: While the course of ILD in the native and transplanted lungs varied in this series, these cases illustrate that disease progression is common in the native lung, suggesting that either the immune process continues to target autoantigens or ongoing fibrotic pathways are active in the native lung. Mild lung disease may occur in the allograft after several years due to either allograft rejection or recurrent mild ILD.
Authors: Eric A Hoffman; Anne V Clough; Gary E Christensen; Ching-Long Lin; Geoffrey McLennan; Joseph M Reinhardt; Brett A Simon; Milan Sonka; Merryn H Tawhai; Edwin J R van Beek; Ge Wang Journal: Acad Radiol Date: 2004-12 Impact factor: 3.173
Authors: B Etienne; M Bertocchi; J P Gamondes; F Thévenet; C Boudard; T Wiesendanger; R Loire; J Brune; J F Mornex Journal: Am J Respir Crit Care Med Date: 1998-01 Impact factor: 21.405
Authors: Peter D Sottile; David Iturbe; Tamiko R Katsumoto; M Kari Connolly; Harold R Collard; Lorriana A Leard; Steven Hays; Jeffrey A Golden; Charles Hoopes; Jasleen Kukreja; Jonathan P Singer Journal: Transplantation Date: 2013-04-15 Impact factor: 4.939
Authors: Donald P Tashkin; Elizabeth R Volkmann; Chi-Hong Tseng; Hyun J Kim; Jonathan Goldin; Philip Clements; Daniel Furst; Dinesh Khanna; Eric Kleerup; Michael D Roth; Robert Elashoff Journal: Ann Rheum Dis Date: 2014-12-01 Impact factor: 19.103
Authors: Masaaki Sato; Thomas K Waddell; Ute Wagnetz; Heidi C Roberts; David M Hwang; Ayesha Haroon; Dirk Wagnetz; Cecilia Chaparro; Lianne G Singer; Michael A Hutcheon; Shaf Keshavjee Journal: J Heart Lung Transplant Date: 2011-03-17 Impact factor: 10.247
Authors: H Schurawitzki; R Stiglbauer; W Graninger; C Herold; D Pölzleitner; O C Burghuber; D Tscholakoff Journal: Radiology Date: 1990-09 Impact factor: 11.105
Authors: Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin Journal: Expert Rev Respir Med Date: 2022-01-31 Impact factor: 3.772